Yan Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yan Zhou has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
- Roshan J. Thapa
Blood Cell Development and Function Program, Fox Chase Cancer Center , Philadelphia, PA 19111
25 shared publications - Siddharth Balachandran
Center for Immunology, Fox Chase Cancer Center, Philadelphia, USA
25 shared publications - Alexander Muir
Ben May Department for Cancer Research, University of Chicago
17 shared publications - Allison N. Lau
Koch Institute for Integrative Cancer Research and the Department of Biology at Massachusetts Institute of Technology, Cambridge, MA 02139, USA
17 shared publications - Andres J. Klein-Szanto
Histopathology Facility, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
17 shared publications - Diana Restifo
Fox Chase Cancer Center, Philadelphia, PA
17 shared publications
Latest Publications
- Open Access
- 14 December 2023
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 52 (1) , S90
230: STOKES-ADAMS SYNDROME! ATYPICAL PRESENTATION OF FULMINANT MYOCARDITIS
- 14 December 2023
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 52 (1) , S90
Open Access230: STOKES-ADAMS SYNDROME! ATYPICAL PRESENTATION OF FULMINANT MYOCARDITIS
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Targeted Blockade of JAK/STAT3 Signaling Inhibits Ovarian Carcinoma Growth
Ovarian carcinoma is the fifth leading cause of death among women in the United States. Persistent activation of STAT3 is frequently detected in ovarian carcinoma. STAT3 is activated by Janus family kinases (JAK) via cytokine receptors, growth factor receptor, and non–growth factor receptor tyrosine kinases. Activation of STAT3 mediates tumor cell proliferation, survival, motility, invasion, and angiogenesis, and recent work demonstrates that STAT3 activation suppresses antitumor immune responses and supports tumor-promoting inflammation. We hypothesized that therapeutic targeting of the JAK/STAT3 pathway would inhibit tumor growth by direct effects on ovarian carcinoma cells and by inhibition of cells in the tumor microenvironment (TME). To test this, we evaluated the effects of a small-molecule JAK inhibitor, AZD1480, on cell viability, apoptosis, proliferation, migration, and adhesion of ovarian carcinoma cells in vitro. We then evaluated the effects of AZD1480 on in vivo tumor growth and progression, gene expression, tumor-associated matrix metalloproteinase (MMP) activity, and immune cell populations in a transgenic mouse model of ovarian carcinoma. AZD1480 treatment inhibited STAT3 phosphorylation and DNA binding, and migration and adhesion of cultured ovarian carcinoma cells and ovarian tumor growth rate, volume, and ascites production in mice. In addition, drug treatment led to altered gene expression, decreased tumor-associated MMP activity, and fewer suppressor T cells in the peritoneal TME of tumor-bearing mice than control mice. Taken together, our results show pharmacologic inhibition of the JAK2/STAT3 pathway leads to disruption of functions essential for ovarian tumor growth and progression and represents a promising therapeutic strategy. Mol Cancer Ther; 14(4); 1035–47. ©2015 AACR.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Targeted Blockade of JAK/STAT3 Signaling Inhibits Ovarian Carcinoma Growth
Ovarian carcinoma is the fifth leading cause of death among women in the United States. Persistent activation of STAT3 is frequently detected in ovarian carcinoma. STAT3 is activated by Janus family kinases (JAK) via cytokine receptors, growth factor receptor, and non–growth factor receptor tyrosine kinases. Activation of STAT3 mediates tumor cell proliferation, survival, motility, invasion, and angiogenesis, and recent work demonstrates that STAT3 activation suppresses antitumor immune responses and supports tumor-promoting inflammation. We hypothesized that therapeutic targeting of the JAK/STAT3 pathway would inhibit tumor growth by direct effects on ovarian carcinoma cells and by inhibition of cells in the tumor microenvironment (TME). To test this, we evaluated the effects of a small-molecule JAK inhibitor, AZD1480, on cell viability, apoptosis, proliferation, migration, and adhesion of ovarian carcinoma cells in vitro. We then evaluated the effects of AZD1480 on in vivo tumor growth and progression, gene expression, tumor-associated matrix metalloproteinase (MMP) activity, and immune cell populations in a transgenic mouse model of ovarian carcinoma. AZD1480 treatment inhibited STAT3 phosphorylation and DNA binding, and migration and adhesion of cultured ovarian carcinoma cells and ovarian tumor growth rate, volume, and ascites production in mice. In addition, drug treatment led to altered gene expression, decreased tumor-associated MMP activity, and fewer suppressor T cells in the peritoneal TME of tumor-bearing mice than control mice. Taken together, our results show pharmacologic inhibition of the JAK2/STAT3 pathway leads to disruption of functions essential for ovarian tumor growth and progression and represents a promising therapeutic strategy. Mol Cancer Ther; 14(4); 1035–47. ©2015 AACR.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S3 from Targeted Blockade of JAK/STAT3 Signaling Inhibits Ovarian Carcinoma Growth
Supplementary Figures S1-S3: Supplementary Figure S1. AZD1480 abrogates STAT3 DNA binding while targeting JAK2 or STAT3 has little effect on viability or proliferation in cultured cells. Supplementary Figure S2. Pharmacodynamics of AZD1480 treatment. Supplementary Figure S3. Flow cytometry analysis of immune cell subpopulations in tumors and peritoneal washes from vehicle- and AZD1480-treated mice.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S3 from Targeted Blockade of JAK/STAT3 Signaling Inhibits Ovarian Carcinoma Growth
Supplementary Figures S1-S3: Supplementary Figure S1. AZD1480 abrogates STAT3 DNA binding while targeting JAK2 or STAT3 has little effect on viability or proliferation in cultured cells. Supplementary Figure S2. Pharmacodynamics of AZD1480 treatment. Supplementary Figure S3. Flow cytometry analysis of immune cell subpopulations in tumors and peritoneal washes from vehicle- and AZD1480-treated mice.